











































Atlas of Lobular Breast Cancer Models: Challenges and Strategic
Directions
Citation for published version:
Sflomos, G, Schipper, K, Koorman, T, Fitzpatrick, A, Oesterreich, S, Lee, A, Jonkers, J, Brunton, VG,
Christgen, M, Isacke, C, Derksen, PWB & Brisken, C 2021, 'Atlas of Lobular Breast Cancer Models:
Challenges and Strategic Directions', Cancers. https://doi.org/10.3390/cancers13215396
Digital Object Identifier (DOI):
10.3390/cancers13215396
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Dec. 2021
cancers
Review
Atlas of Lobular Breast Cancer Models: Challenges and
Strategic Directions
George Sflomos 1,* , Koen Schipper 2 , Thijs Koorman 3, Amanda Fitzpatrick 2, Steffi Oesterreich 4,5,6 ,
Adrian V. Lee 4,5,6, Jos Jonkers 7,8 , Valerie G. Brunton 9, Matthias Christgen 10, Clare Isacke 2,
Patrick W. B. Derksen 3 and Cathrin Brisken 1,2,*,† on behalf of the ELBCC–LOBSTERPOT CA19138 Action


Citation: Sflomos, G.; Schipper, K.;
Koorman, T.; Fitzpatrick, A.;
Oesterreich, S.; Lee, A.V.; Jonkers, J.;
Brunton, V.G.; Christgen, M.; Isacke,
C.; et al. Atlas of Lobular Breast
Cancer Models: Challenges and





Received: 25 September 2021
Accepted: 21 October 2021
Published: 27 October 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 ISREC—Swiss Institute for Experimental Cancer Research, School of Life Sciences,
Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
2 The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK;
koen.schipper@icr.ac.uk (K.S.); amanda.fitzpatrick@icr.ac.uk (A.F.); clare.isacke@icr.ac.uk (C.I.)
3 Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100,
3584 CX Utrecht, The Netherlands; T.Koorman@umcutrecht.nl (T.K.);
P.W.B.Derksen@umcutrecht.nl (P.W.B.D.)
4 Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA;
oesterreichs@upmc.edu (S.O.); leeav@upmc.edu (A.V.L.)
5 Magee Women’s Cancer Research Institute, Pittsburgh, PA 15213, USA
6 Cancer Biology Program, Women’s Cancer Research Center, UPMC Hillman Cancer Center,
Pittsburgh, PA 15232, USA
7 Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands;
j.jonkers@nki.nl
8 Oncode Institute, 1066 CX Amsterdam, The Netherlands
9 Edinburgh Cancer Research UK Centre, Institute of Genetics and Cancer, University of Edinburgh,
Crewe Road South, Edinburgh EH4 2XU, UK; v.brunton@ed.ac.uk
10 Institute of Pathology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany;
christgen.matthias@MH-Hannover.de
* Correspondence: georgios.sflomos@epfl.ch (G.S.); cathrin.brisken@epfl.ch (C.B.);
Tel.: +41-216930784 (G.S.); +41-216930781 (C.B.)
† Collaborators of the ELBCC–LOBSTERPOT CA19138 Action.
Simple Summary: Invasive lobular breast cancer (ILC) is the second most common histological
subtype of invasive breast cancer, which is noted to have a unique microscopic appearance. The
understanding of ILC biology is advancing through the evolution of various experimental models,
with the ultimate aim to discover new therapeutic strategies. In this review, we summarize the critical
developments in the modeling of ILC. We provide a comprehensive overview of well-established
ILC models and discuss different approaches for modeling the disease. We highlight the potential
opportunities, the challenges, and the recent advances that have contributed to a better understanding
of ILC and envisage the future of ILC modeling.
Abstract: Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases
and responds well to endocrine treatment when estrogen receptor α-positive (ER+) yet differs in
many biological aspects from other ER+ BC subtypes. Up to 30% of patients with ILC will develop
late-onset metastatic disease up to ten years after initial tumor diagnosis and may experience failure
of systemic therapy. Unfortunately, preclinical models to study ILC progression and predict the
efficacy of novel therapeutics are scarce. Here, we review the current advances in ILC modeling, in-
cluding cell lines and organotypic models, genetically engineered mouse models, and patient-derived
xenografts. We also underscore four critical challenges that can be addressed using ILC models: drug
resistance, lobular tumor microenvironment, tumor dormancy, and metastasis. Finally, we highlight
the advantages of shared experimental ILC resources and provide essential considerations from
the perspective of the European Lobular Breast Cancer Consortium (ELBCC), which is devoted to
better understanding and translating the molecular cues that underpin ILC to clinical diagnosis and
intervention. This review will guide investigators who are considering the implementation of ILC
models in their research programs.
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1. Search Strategy and Selection Criteria
References for this review were obtained from Medline, Google Scholar, and SCOPUS
searches using the keywords “lobular breast cancer models”, “ILC models”, “genetically
engineered mouse model”, “ILC patient-derived xenografts”, “breast cancer xenografts”,
“breast cancer organoids”, and “preclinical models” and there was no restriction on year of
publication. Databases used included cellosaurus (https://web.expasy.org/cellosaurus/,
accessed date: 1 October 2021) [1], German Collection of Microorganisms and Cell Cultures
GmbH (DSMZ, https://www.dsmz.de/), American Type Culture Collection (ATCC, https:
//www.lgcstandards-atcc.org/?geo_country=ch, accessed date: 1 October 2021), Rikagaku
Kenkyūjo Cell Bank (RIKEN, https://cell.brc.riken.jp/en/), European Collection of Au-
thenticated Cell Cultures (ECACC, http://www.hpacultures.org.uk/collections/ecacc.jsp,
accessed date: 1 October 2021), Japanese Cancer Research Resources Bank (JCRB, https://
cellbank.nibiohn.go.jp/english/cellsearch_e/, accessed date: 1 October 2021), Interlab Cell
Line Collection (ICLC, http://www.iclc.it/Listanuova.html), Korean Cell Line Bank (KCLB,
http://cellbank.snu.ac.kr/english/index.php, accessed date: 1 October 2021), the Mouse
Genome Database (MGD, http://www.informatics.jax.org/, accessed date: 1 October 2021),
Cell Model Passports (https://cellmodelpassports.sanger.ac.uk/passports/SIDM00241,
accessed date: 1 October 2021), the SUM Breast Cancer Cell Line Knowledge Base (SLKBase,
https://sumlineknowledgebase.com/, accessed date: 1 October 2021), cBioPortal for Can-
cer Genomics (https://www.cbioportal.org/), the Human Cancer Models Initiative (HCMI,
https://ocg.cancer.gov/programs/HCMI, accessed date: 1 October 2021), the Cancer
Dependency Map https://depmap.org/portal/, the International Agency for Research on
Cancer (IARC) TP53 Database (https://p53.iarc.fr/CellLines.aspx, accessed date: 1 October
2021), Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle, ac-
cessed date: 1 October 2021), PDX Finder (https://www.pdxfinder.org/), DepMap project
(https://depmap.org/portal/, accessed date: 1 October 2021), and COSMIC cell-line
project (https://cancer.sanger.ac.uk/cell_lines, accessed date: 1 October 2021).
2. Introduction
Invasive lobular carcinoma (ILC) is the most frequent special histological breast cancer
(BC) subtype and accounts for at least 15% of all female BC cases [2–5]. The vast majority
of primary ILC have a low proliferative index, express the estrogen receptor (ER) and
the progesterone receptor (PR), and show only rare amplification of HER2. Compared
to patients diagnosed with ER+/PR+/HER2− no special type invasive BC (NST, also
known as invasive ductal carcinoma), those with ILC do not show additional benefit of
adjuvant chemotherapy [6], tend to have larger tumors on presentation, an increased
number of involved lymph nodes, and lower detection through mammographic screening
compared to magnetic resonance imaging (MRI) [7]. ILC is also generally characterized by
an increased risk of late recurrence [8], which can in part be attributed to the reawakening
of quiescent disseminated tumor cells. Histologically, classic ILC typically shows single-
cell infiltration and often a targetoid pattern of invasion [9]. Of note, ILC presents with
a unique pattern of metastatic spread to bones, ovaries, peritoneum, leptomeninges, GI
tract [10–16], and rarer sites, including the orbital cavity [11]. Spread to the lungs and other
visceral organs is less frequently observed than other ER+ BCs [17–19]. The reasons for this
organotropism are not understood but are likely to be governed by intrinsic anchorage-
independent tumor characteristics due to the inherent loss of E-cadherin [20] along with
different therapies, systemic factors, and microenvironmental cues priming distinct pre-
metastatic niches within different organs [21].
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At the molecular level, primary ILC has a distinct genomic landscape from NST [22–24].
First, the mutational inactivation of E-cadherin (encoded by CDH1) provides a biochemical
signature that promotes ILC dissemination through anoikis resistance [25] and amplifies en-
dogenous growth factor receptor (GFR) signals [26,27]. Second, mutations in ERBB2, ERRB3
and/or PIK3CA further enhance these oncogenic GFR signals by directly activating the
PI3K/AKT pathway. Finally, primary ILCs have distinct immune microenvironments with
low levels of tumor-infiltrating lymphocyte (TILs) and a different immune cell composition
compared to ER+/HER2− NSTs [28,29]. Less is known about the mutational repertoire of
ILC metastases. In a recent study, TP53 and ESR1 mutations were more frequent in ILC
metastases, tumor mutational burden was higher in ILC metastases, and RHOA mutations
were more frequent in ovarian ILC metastasis [14]. Despite these differences, patients with
ILC are treated similarly to patients with NST, which highlights the need to understand
the molecular underpinnings of ILCs to inform advanced treatment options.
Laboratory models are vital for helping us understand the biology of ILC (Figure 1) [2].
Despite attempting to develop ILC cell lines using many different culture conditions and
varying starting material, the generation of long-lived established ILC cell lines has been
unsuccessful. Moreover, the number of relevant and well-established ILC models remains
limited due to the lower incidence of ILC, fewer ILC patients in clinical trials, and the
intrinsic characteristics of ILCs that do not readily transplant/grow as organoids. This
study systematically reviews the in vitro, ex vivo, and in vivo experimental models, aiming
to provide a comprehensive summary of the existing ILC models, exploring their strengths
and weakness, and paying particular attention to the recent and future advances of ILC
modeling (Figure 1 and Table 1).
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Table 1. Milestones timeline of key lobular models development and their applications. Chronological list of the key ILC
models leading to existing lobular models and their established and future applications. Abbreviations: P, proliferation; TN,
triple negative; GEM model, genetically engineered mouse model; LCIS, lobular carcinoma in situ; I, invasion; TP, tumor
progression; EnR, endocrine response, and resistance; HoR, hormone responsiveness; C, chemoresistance; D, dormancy; M,
metastasis; MM134, MDA-MB-134-VI; SUM44, SUM-44PE; PMID, PubMed identifier; PILC, pleomorphic ILC; SR, signet
ring morphology; T, targetoid; R, round; SF, single-cell-file pattern. Color code: green, cell lines in vitro; grey, GEMMs;
orange, organoids; purple, xenografts, and PDXs.
Year Model Significance MorphologicalCharacteristics Applications PMID
1974 MDA-MB-134-VI
First ILC cell line -
expansion/characterization
(in vitro)
R, SF P, EnR, HoR, DrR 4412247
1978 SUM-44PE
ILC cell line -
expansion/characterization
(in vitro)
R, SF P, EnR, HoR, DrR 8425198
2006 Cdh1; Trp53
First GEM ILC model
Rational: CDH1 is an ILC
hallmark
PILC LCIS, P, TP, I, DrR,D, M 17097565
2008 SUM-44PEvariants
Studies on endocrine resistance
(in vitro) R, SF P, EnR 18974135
2009
2012 IPH-926
First well characterized TN ILC







First ILC PDXs LCIS, PILC, SR, SF P, TP, EnR, HoR,DrR, D, M 22019887
2016 Cdh1; Pten
GEM ILC model.
Rational: PTEN loss found in
~10% of ILCs






First intraductal ILC PDXs LCIS, PILC, SR, SF LCIS, P, TP, I, EnR,HoR, DrR, D, M
30430577
19191266




found in ~40% of ILCs





First intraductal SUM-44PE and
MDA-MB-134-VI xenografts LCIS, PILC, SR, SF
LCIS, P, TP, I, EnR,
HoR, DrR, D, M 33616307
3. In Vitro Cell-Based ILC Models
Human-derived cell lines have been the mainstay of cancer research [30]. However,
the list of authenticated ILC lines is short, with limited patient-related clinical and treatment
information available. Only a handful of ILC cell lines have been extensively studied. ILC
cell lines proliferate significantly slower than their NST line counterparts, and only a few
of them derived from primary tumors but most from pleural effusions or ascites, i.e., late
metastatic disease (Table 2). In addition, almost all of them were derived from Caucasian
females [31]. Although 90% of ILCs are ER+/PR+, only a minority of the available models
express ER. As expected, most of them have pathogenic CDH1 mutations, but although
only 8% of clinical ILCs have altered TP53 [23,32], the widely used ILC models express
mutant TP53 (Table 2, Supplementary File S1).
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Table 2. ILC and ILC-like cell lines. Information was collected from published literature. Widely used ILC and ILC-like
breast cancer cell lines. Abbreviations: MA, malignant ascites; PF, pericardial fluid; BM, bone metastasis; OvM, ovarian
metastases; ER, estrogen receptor; NST, non-special type; PE, pleural effusion; BmM, bone marrow metastases; n/a, not
available; Ref, reference(s); *, premature termination (stop) codon; npy, not published yet. See also expanded table at
Supplemental File S1.
Name Tissue Tumor Biomarker E-Cadherin/CDH1 Morphology Ref.
ILC Cell Lines
SUM-44 PE PE ILC ER+, PRlow, HER2− p.F423LfsX8 Rounded [33]
IPH-926 MA ILC ER−, PR−, HER2− p.V82fsX93 Rounded [34]
MDA-MB-134-VI PE NST ER+, PR−, HER2− p.L230EfsX4 Rounded [33]
MDA-MB-330 PE ILC ER+/−, PR−, HER2+ wt Rounded [35]
UACC-3133 PE ILC ERlow, PR−, HER2+ n/a n/a [36]
MA-11 BmM ILC ER−, PR−, HER2− n/a Rounded [37]
WCRC-25 PE ILC ER−, PR−, HER2− p.Q706 * Rounded npy
ILC-Like Cell Lines
BCK4 PE ILC(mucinous) ER
+, PR+, HER2− n/a Rounded [38]
MDA-MB-453 PF n/a ER−, PR−, HER2+ p.W638X Rounded [39]
MDA-MB-468 PE n/a ER−, PR−, HER2− wt Rounded [39]
CAMA-1 PE Solid ER+, PR+, HER2− p.Y523_G571del Rounded [39]
SK-BR-3 PE n/a ER−, PR−, HER2+ c.1_1936del1936 Rounded [35]
SK-BR-5 n/a n/a ER−, PR−, HER2+ p.I178TfsX32 n/a [40]
EVSA-T AF n/a ER−, PR− p.V216_T229del Rounded [41]
CAL-148 PE n/a ER−, PR−, HER2− D402N, deep deletion n/a [42]
ZR-75-30 AF NST ER+, PR−, HER2+ p.Glu243Ter-p.E243X Rounded [43]
HCC2218 PBC NST ER−, PR−, HER2+ c.1-832del Rounded [44]
600MPE PE NST n/a p.Y380_K440del Rounded [45]
BT549 n/a Papillary ER−, PR−, HER2− n/a Rounded [46]
MA-11 n/a ILC andtubular ER
−, PR−, HER2− wt Rounded [37]
OCUB-1F PE n/a ER−, PR− p.Val17fs*1 Rounded [47]
3.1. E-cadherin-Deficient Well-Characterized ILC Cell Lines
SUM-44PE are widely used ILC cells isolated from a pleural effusion of a patient unre-
sponsive to both endocrine treatment and chemotherapy with ER+ ILC in 1993. SUM-44PE
cells possess a CDH1 point mutation, leading to no detectable E-cadherin protein levels.
Moreover, these cells harbor truncating TP53 mutation, which leads to low transcripts
and p53 expression [48]. SUM-44PE expresses high ER protein levels, and both CCND1
(Cyclin D1) and FGFR1 are amplified [49]. Interestingly, a deleterious ESR1Y537S mutation,
frequently found in refractory ILC [50], pre-exists in a fraction (one out of a million) of
in vitro 2D-cultured SUM-44PE cells and is readily detectable within 12 weeks following
the transfer of the cells to estrogen-free medium [51]. Copy number changes, mutational
data, and genome-wide expression have been extensively described at the SUM Breast
Cancer Cell Line Knowledge Base (SLKBase) [52].
IPH-926 cells, derived from the ascites of a patient with an endocrine and chemotherapy-
resistant metastatic ILC relapse, are the second well-characterized ILC model [34]. IPH-926
cells are triple negative (TN), like the therapy-refractory ILC relapse of the corresponding
patient. However, the corresponding primary tumor of the patient, which was diagnosed
16 years before the establishment of the IPH-926 cell line, was a grade 1 ER+ ILC [34].
Accordingly, IPH-926 cells reflect the tumor biology of a late-stage ILC after many years of
tumor progression and ER status conversion under clinical therapy. IPH-926 cells harbor a
CDH1 frameshift mutation and lack E-cadherin protein expression (Figure 2). The same
CDH1 frameshift mutation was demonstrated in the primary ILC of the corresponding pa-
tient [34]. IPH-926 cells display a luminal gene expression profile, despite the loss of ER and
lack of PR and AR expression [53]. IPH-926 cells lack PIK3CA mutation, but the PI3K/AKT
pathway is intrinsically activated [27]. Notably, IPH-926 are temperature-sensitive due to
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endogenous expression of a temperature-sensitive (ts) p53 mutant (ts TP53 E285K), which
can toggle between wild-type function and loss of function states, depending on the cell
culture temperature [54]. Interestingly, this TP53 mutation occurred as a secondary genetic
event during the clonal evolution of the respective ILC in the corresponding patient. The
occurrence of the TP53 E285K mutation was associated with a morphological shift to a
G3-differentiated ILC with pleomorphic features in the corresponding clinical tumor speci-
mens. Furthermore, IPH-926 cells display overexpression of the BC anti-estrogen resistance
4 (BCAR4) gene, which has been linked to hormone-independent tumor cell growth [55–57],
display overexpression of the MDR1/ABCB1 drug transporter, and actively extrude con-
ventional chemotherapeutic agents, such as doxorubicin, in an MDR1/ABCB1-dependent
manner [56]. Overexpression of MDR1/ABCB1 in IPH-926 is likely related to palliative
poly-chemotherapy administered to the corresponding patient before this cell line was
derived from ascites. Finally, IPH-926 cells also lack beta-catenin protein expression and
are tumorigenic in SCID female mice [34].
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The MDA-MB-134-VI line is a well-accepted ER+ ILC model, yet derived from the
pleural fluid of a patient diagnosed with a primary ductal papillary mammary carcinoma.
Molecular reclassification revealed that these cells belong to the luminal molecular sub-
type, and based on genetic and expression profiles, resemble classic lobular carcinomas
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(CLC) [58]. Concomitantly, MDA-MB-134-VI does not express E-cadherin due to truncating
mutations (deletion of exon 6) and appears to be de novo tamoxifen-resistant [33,59]. In
2D culture, these cells form grape-like clusters, and E-cadherin/p120 catenin dual staining
shows diffuse cytoplasmic p120, further confirming that MDA-MB-134-VI represents an
ILC cell line [60]. MDA-MB-134-VI cells also show FGFR1 amplification and have been
proposed as a model system for the preclinical investigations of BCs with FGFR1 overex-
pression [58]. However, these cells also contain an oncogenic KRAS mutation uncommon
in ILC and may override the proximal GFR dependence and induce attenuation of drugs
targeting FGFR1 or PI3K/AKT [61]. Additional E-cadherin-deficient ILC lines are, to a
high degree, not well characterized and not widely used, including UACC-3133, MA-11,
EFM-63, and the discontinued HCC-2185 cells (Table 2 and Supplementary File S1).
3.2. ILC-like Cell Lines Derived from Clinical NSTs with ILC Molecular Features (Genetic and
Expression Profile)
Eleven BC cell lines are annotated as “carcinoma”, “adenocarcinoma” or “ductal
carcinoma”, with no detailed pathology report or molecular analysis of the corresponding
clinical tumor specimens available, yet recent data show that they have key ILC genetic
features, such as CDH1 mutation.
BCK4 cells derived from the solid tumor xenograft of a poorly differentiated mucinous
adenocarcinoma readily switch to an ILC morphology with mucinous features when mice
are supplemented with E2 [38,62]. BCK4 cells exhibit a partial tamoxifen agonism similar
to MDA-MB-134-VI cells, express low levels of PR, its growth is markedly accelerated by
E2, and have been suggested as a TP53 wild type ILC model [63].
SK-BR-3 is an ER− cell line with an amplified ERBB2 locus that overexpresses Her-
2/neu and is sensitive to lapatinib [64]. SK-BR-3 cells have been demonstrated as a valuable
preclinical model to explore resistance mechanisms to HER2-targeted therapies and screen
for new drugs [35,65]. SK-BR-3 cells do not express E-cadherin due to a large homozygous
deletion commonly found in ILCs and therefore form loosely cohesive grape-like or stellate
structures [35,66,67]. They express well-differentiated luminal epithelial-like phenotype
markers but do not grow well in vivo [68], with few exceptions, including the formation of
poorly differentiated tumors in immunocompromised mice [69].
MDA-MB-453 cells were obtained from the malignant pericardial fluid consistent
with the metastatic propensity of ILCs to the serosal cavities. As this cell line expresses
androgen receptor (AR), it has been traditionally used as an apocrine BC model [70].
Notably, apocrine differentiation has also been described in the pleomorphic ILC [71].
Due to nonsense CDH1 mutation, the cells present with non-functional E-cadherin [72].
They belong to the grape-like class of cell lines, which form colonies with poor cell–
cell contacts [73]. Notably, cells with grape-like phenotype typically express moderate
levels of HER2 [73]; herein, MDA-MB-453 express both HER2 and HER3 proteins [74,75].
Interestingly, MDA-MB-453 cells also have an inactivating PTEN mutation found in at least
10% of ILCs [22].
ZR-75-30 is a luminal-like cell line derived from the ascitic fluid of a woman with
primary NST [43]. It is of particular interest as it expresses ER and shows a rounded
epithelial morphology [43,76]. ZR-75-30 cells also overexpress HER2, which has also been
found amplified in ILC [49,69] and have traditionally been used as an ER+ BC model
insensitive to tamoxifen, yet its growth is stimulated by progesterone [77].
CAMA-1 was derived from a solid BC with scirrhous regions. CAMA-1 cells are
ER+/PR+, responsive to estrogen, and sensitive to growth inhibition by tamoxifen. More-
over, CDH1 is genetically inactivated via biallelic in-frame mutations and deletion of exon
6, resulting in a shortened, non-functional E-cadherin protein yet detectable at the cell
membrane and weakly diffuse in the cytoplasm [78]. Morphologically the cells grow as
small, loosely packed epithelial-like cells [79] with wild-type GATA3 consistent with fewer
GATA3 mutations found in primary ILC versus NST tumors [22] and are HER2-negative.
600MPE is an ER+ line with a large CDH1 deletion, resulting in a shortened, non-
functional E-cadherin protein, yet the original clinical diagnosis was NST BC [45].
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The ER+ circulating tumor cell line CTC-ITB-01 was derived from the peripheral blood
of a female patient with bilateral mammary carcinoma of a well-differentiated ILC on the
left breast and NST on the right breast [80]. CTC-ITB-01 carries a “private” variant in the
CDH1 gene (c.1204G>A; p.D402N), an uncharacterized missense pathogenic (predicted)
mutation in the E-cadherin extracellular domain 3 (EC3) identical to the one found in CAL-
148 cells. Notably, the EC3 domain is necessary for homophilic E-cadherin adhesion, and it
remains to be seen how this model will represent ILC phenotypes. Additionally, ILC-like
cell lines, with genetic CDH1 inactivation and a rounded epithelial-like morphology that
warrant further molecular characterization, include EVSA-T [41], OCUB-1F [47], CAL-
148 [42], and HCC2218 [44] (Table 2).
Together, CDH1 defective ILC-like cell lines are often TN, androgen receptor-positive
(AR+), or overexpress HER2. Interestingly, clinical studies have shown that primary
TN-ILC, at the molecular level, is characterized by increased AR signaling and frequent
alterations in HER2 network proteins [81]. In addition, HER2/3 mutations are relatively
common, particularly in the pleomorphic ILC subtype [3,82–86], and HER2 overexpression
is reported in primary ILCs [62].
3.3. Epigenetic Inactivation of E-Cadherin
Along with truncating mutations and allelic CDH1 loss, epigenetic silencing is an
additional but less common and questionable mechanism for the lack of E-cadherin expres-
sion [22]. Methylation of 5′ CpG islands has been described for many carcinomas, including
gastric [87], skin [88], and ILC [89]. Epigenetic silencing of E-cadherin is considered a
non-driver and late event in ILC progression [20]. This epigenetics phenomena has been
found in six ILC-like cell lines. These BC cell lines with CDH1 promoter methylation
and without detectable E-cadherin protein were all derived from tumors with a non-ILC
primary diagnosis (BT549 [46], SUM159PT [90], CAL-120 [91], MDA-MB-157 [92,93], MDA-
MB-436 [39], and HS578T [94]). These lines would need further evaluation as putative ILC
models (see Table 2 and Supplementary File S1).
3.4. ILC Lines with Proficient E-Cadherin and Defective Adherens Junctions
Impaired adherens junctions, a hallmark of ILC phenotype, may also be affected by
α-catenin (CTNNA1) loss rather than lack of E-cadherin itself. For example, aberrant E-
cadherin-dependent cell–cell adhesions in the PC-3 prostate cancer line are dictated not by
loss of E-cadherin but by the lack of α-catenin [95]. Likewise, there is one ILC line and three
ILC-like E-cadherin positive BC lines with non-functional adherens junctions. E-cadherin
expressing MDA-MB-330 cells were derived from pleural effusion of a patient with ILC
and grew out as polygonal cells in islands [39]. However, they have non-functional ad-
herens junctions because of a biallelic CTNNA1 mutation (truncating α-catenin) to impair
E-cadherin function [2] and have been used as an ILC model in 2D and 3D in vitro stud-
ies [63]. In these cells, ERBB2 is amplified, and β-catenin is expressed in the absence of
α-catenin. MDA-MB-468 is an Rb-deficient cell line that expresses E-cadherin and has
acquired CTNNA1 bi-allelic mutations [39]. In vitro, MDA-MB-468 cells show a typical
ILC-type growth. However, in vivo, they only grow if they are co-injected with 3T3HAS3
fibroblasts [96]. This line was initially classified as basal-like, but recent reclassification
based on the whole transcriptome profile showed more similarity to the luminal/HER2
group [97]. Two additional less characterized ILC-like cell lines with CTNNA1 mutant are
MDA-MB-157 [92] and HCC1187 [44].
3.5. ILC Cell Lines Developed from Patient-Derived Xenografts (PDXs)
Stable cell lines can be generated once they have passed via in vivo xenograft growth.
However, with regard to ILC, only one cell line (UCD178) has been generated directly after
fourteen months of continuous in vitro culturing of dissociated PDX xenografted cells [98].
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3.6. Experimental CDH1 Downregulation/Deletion in E-Cadherin-Positive Non-ILC Cells
Loss of E-cadherin expression is a hallmark of ILCs. Therefore, silencing or knockout
of CDH1 in non-ILC cells has been considered a reasonable alternative to model ILC
mechanistically. E-cadherin-null isogenic partners have been generated for human ER+
NST lines MCF7 [90], T47D, and MDA-MB-468, the murine 4T1 cells [99], as well from
the non-malignant breast epithelial MCF10A cells and primary cells isolated from normal
breast tissue [100–105]. Interestingly, E-cadherin deficiency in non-ILC cells is insufficient to
induce an EMT [100]. For example, the E-cadherin deficiency MCF7 cells display rounded
morphology, as seen in ILC cells harboring naturally occurring E-cadherin mutations [90],
and grow 3.5-fold less than the controls when grafted in the mouse milk ducts [106].
Moreover, lentiviral knockdown of E-cadherin expression in NST TN PDX organoids
significantly increases invasion and dissemination and decreases colony formation [107].
Notably, isogenic MCF7 cells with frameshift CDH1 mutations and concomitant loss
of E-cadherin expression (Supplementary File S1) have been proven valuable tools for bio-
chemical and synthetic lethality studies [90,108]. Notably, both ROLO (NCT03620643) and
ROSALINE (NCT04551495) clinical trials targeting ROS1 are based on synthetic lethality
studies [27,90,109].
3.7. Ongoing Efforts for the Generation of Additional ILC Lines
The generation of additional BC cell lines from primary and metastatic tumors is
essential for experimental ILC studies but has proven challenging. However, a recent
exception is the generation of WCRC25, an ILC cell line generated from a pleural effusion
from a patient with ILC (Elangovan et al., submitted abstract for SABCS 2021). The cell line
is characterized by loss of E-cadherin due to a missense mutation in CDH1 coupled with
the loss of heterozygosity of the other allele (Table 2). Like the majority of BC cell lines,
WCRC25 has a TP53 mutation. Although the pleural effusion was weakly ER+, WCRC25
lacks ER expression and does not respond to estrogen. RNA sequencing revealed activation
of AKT signaling, which should be further explored in future studies.
4. ILC Cell Line-Based 3D Models and Ex Vivo Patient-Derived 3D Tumor
Organoids (PDOs)
Recently, multidisciplinary efforts to optimize experimental models have led to the
emergence of novel approaches involving 3D culture formats, organoids, spheroids, organ-
otypic cultures of tissue slices or co-cultures, and bioengineered materials which more
faithfully reflect the intra-tumoral heterogeneity and the spatial, biochemical, and me-
chanical properties of the malignant tumor than 2D plastic dish cultures [110–115]. Three-
dimensional culturing of ILC cell lines has sparsely been reported; literature is currently
limited to the comprehensive 2D and 3D phenotypic characterization of only four ER+
human ILC cell lines: MDA-MB-134-VI, SUM-44PE, MDA-MB-330, and BCK4 (Table 3,
Supplementary File S1) [63]. The growth of NST and ILC cell lines in 3D suspension
culture environments confirmed the remarkable anchorage-independent growth charac-
teristics unique to ILC cells [63]. Although ILC cell lines show different morphologies
when they grow in 3D extracellular matrix (ECM) gels and divergent adhesive properties
on matrix proteins, overall display a “grape-like” morphology previously described for
cells with poor cell–cell adhesion [63]. Moreover, ILC lines show limited migration in the
commonly used wound-scratch assay compared to NST cells. Similarly, in mammosphere
assays, E-cadherin expressing cells successfully propagate as long-term mammosphere
cultures. In contrast, ILC-like SKBR3 and MDA-MB-468 cells form cell clumps that can
be disaggregate mechanically, and only re-expression of E-cadherin allows them to form
mammospheres [116]. The 3D ECM growth of other human ILC cell lines has not been
systematically analyzed.
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Table 3. ILC Patient-Derived Organoids. Expanded table at Supplemental File S1. Abbreviations: HI, Hubrecht Institute;
ICR, The Institute of Cancer Research; UMC, University Medical Center Utrecht; UDL = UMCU Derksen Lab; PILC,
pleomorphic ILC; Ref, reference(s); n/a, not available; npy, not published yet.
Name Type Clinical (Biomarker) Organoids(Biomarkers) E-Cadherin/CDH1 Laboratory/Institute Ref.
Human ILC Organoids (female)
T35 ILC ER+, PR+, HER2− ER+, PR−, HER2+ n/a Prof. HansClevers/HI [117]





ER+, PR+, HER2− ER+, PR+, HER2− n/a Prof. HansClevers/HI [117]
T105 ILC ER+, PR+, HER2− ER+, PR+, HER2− n/a Prof. HansClevers/HI [117]
P008 ILC ER+, PR−, HER2− ER−, PR−, HER2− p.(Ser180Tyr) Prof. ClareIsacke/ICR npy
KCL320 ILC ER+, PR+, HER2− ER−, PR−, HER2− splice variant g.68823627G>A Prof. ClareIsacke/ICR npy
Human ILC Organoids (male)






UDL-WEP9 PILC ER−, PR−, Her2− ER−, PR−, Her2− null Prof. Patrick WBDerksen/UMC npy
UDL-WEP10 PILC ER−, PR−, Her2− ER−, PR−, Her2− null Prof. Patrick WBDerksen/ UMC npy
Primary patient-derived BC organoid (PDO) models better conserve the original ge-
netic status of the primary tumor, probably because the PDO models are cultured relatively
short-term and in the presence of a serum-free medium. Recently, a seminal study de-
veloped a living biobank of breast cancer PDOs [117]. In this resource, 26 primary ILCs
were reported, of which 18 were established as PDO ILC models and were found to have a
unique growth pattern, being grape-like compared to the dense clusters formed by NST
organoids (Table 3, Supplementary File S1). Similarly, another recent report on ILC PDO
reveals that this will be a growing resource for research [118]. Lee/Oesterreich laborato-
ries have developed PDOs from over 20 cases of ILC and find similar grape-like growth
patterns and DNA mutations like those in human ILC (unpublished). Notably, cultur-
ing in 3D laminin-rich matrices, PDO models better retain the histological organization,
differentiation status, and morphologic heterogeneity observed in primary tumors [119].
Although short-term propagation of various freshly dissected primary carcinomas has
been successful, propagation for an extended period has remained challenging.
With PDO technology, primary tumors are typically cultured in a serum-free medium
supplemented with growth factors and basement membrane extract (BME or Matrigel)
matrices. As alternatives to Matrigel, several groups have been experimenting with the
use of neutral hydrogels such as polyethylene glycol (PEG) [120], polyisocyanopeptide
(PIC) hydrogels [121], and sodium alginate [122]. In a recent study, samples from 63 breast
cancer patients, including ten ILCs embedded in alginate, continuously grew in culture for
one month [123]. The architectural features of the encapsulated tissue microstructures were
similar to the original patient tumors, and the organoids were responsive to endocrine
treatments demonstrating active ER signaling.
Finally, collaborative efforts are needed to create and document additional ILC
organoids; the National Cancer Institute, for example, is generating repositories of organoids
from primary and metastatic BC tissues and blood specimens see Appendix A (https:
//pdmr.cancer.gov). More recently, within the ILC research community and the LOBSTER-
POT initiative (https://www.cost.eu/actions/CA19138/), additional (unpublished) ILC
PDO models have become available. They contain primary and metastatic ILC PDOs that
can also be used as PDX models (Supplementary File S1).
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5. ILC Mouse Models
5.1. Genetically Engineered ILC Mouse Models
Over the last two decades, substantial progress has been made in generating geneti-
cally engineered mouse models (GEMMs) of ILC (Figure 3). The prevalence of E-cadherin
loss in ILCs made it a logical target for genetic manipulation; however, initial mouse mod-
els showed that somatic Cre recombinase-mediated loss of E-cadherin in the mammary
epithelium is insufficient to induce tumor formation [25,124]. Moreover, somatic inacti-
vation of E-cadherin in the context of the MMTV-PyMT did not lead to the development
of ILC (Dr. R. Kemler, personal communication). However, stochastic loss of E-cadherin
in combination with deletion of the tumor suppressor p53 resulted in the first GEMM of
ILC, which showed a substantial acceleration of tumor development compared to the loss
of p53 alone [25]. In this GEMM, the cytokeratin 14 (K14) promoter sequence was used
to drive the expression of Cre recombinase, which meant that mice not only developed
mammary tumors but also skin tumors (Table 4, Supplementary File S1).
Table 4. ILC GEMMs. Information was collected from published literature. Abbreviations: Tg, transgenic; CRISPR,
Clustered Regularly Interspaced Short Palindromic Repeats; Cas9, CRISPR-associated protein 9; GEMM-ESC, genetically
engineered mouse model-embryonic stem cell; ILC, invasive lobular carcinoma; ER, estrogen receptor; U of T, University
of Toronto; NKI, Netherlands Cancer Institute; n/t, not tested; n/s, not specified; Ref, reference(s). See also expanded
Supplemental File S1.
Deletion/Activation System Primary Tumor ER Tumor Onset(Weeks) Laboratory/Institute Ref.
Cdh1; Tp53 Tg Pleomorphic ILC Neg. 20–32 Prof. Jos Jonkers/NKI [25]
Cdh1; Pten Tg Classical ILC-likefeatures Pos. 8–16 Prof. Jos Jonkers/NKI [125]
Cdh1 and Pik3ca Tg Immune-relatedILC-like Pos. 5–12 Prof. Sean E. Egan/U of T [126]
Cdh1 and Pten CRISPR/Cas9 Unknown-ILC histology n/t 28 Prof. Jos Jonkers/NKI [127]
Cdh1 and AKTE17K GEMM-ESC Typical ILC histology n/t n/s Prof. Jos Jonkers/NKI [127]
Cdh1 and Myh9 CRISPR/Cas9 Classical ILC-likefeatures n/t n/s Prof. Jos Jonkers/NKI [128]
Cdh1; t-ASPP2 GEMM-ESC Classical ILC-likefeatures n/t 9–15 Prof. Jos Jonkers/NKI [128,129]
Cdh1; Pten; t-ASPP2 GEMM-ESC/Tg Classical ILC-likefeatures n/t 5–9 Prof. Jos Jonkers/NKI [129]
Cdh1; t-MYPT1 GEMM-ESC Classical ILC-likefeatures n/t 10–16 Prof. Jos Jonkers/NKI [128,129]
Cdh1; Pten; t-MYPT1 GEMM-ESC/Tg Classical ILC-likefeatures n/t 5–8 Prof. Jos Jonkers/NKI [129]
Cdh1; Trps1 GEMM-ESC Classical ILC-likefeatures n/t 76 Prof. Jos Jonkers/NKI [130]
Importantly, the ILC lesions developed in these mice induced metastatic dissemination
to the full spectrum of the human metastatic ILC condition. In the next iteration, the use
of the mammary gland-specific whey acidic protein (WAP) promoter sequence to drive
Cre expression gave rise exclusively to mammary tumor formation [131]. The mammary
tumors induced by combined loss of E-cadherin and p53 display a mix of morphologies,
with ER-negative pleomorphic ILC being the most common. Despite being a main driver
event, loss of E-cadherin expression is not seen in all ILCs. Some ILCs retain membranous
E-cadherin expression, while they do display the typical non-cohesive lobular growth
pattern. Apart from extracellular mutations in CDH1 leading to disruption of homotypic
interactions or mutations leading to truncations of the intracellular E-cadherin domains,
disruption of other members of the adherens junction might underlie the lobular growth
pattern in these E-cadherin-proficient ILCs. However, when inactivated in conjunction
with p53, loss of p120 did not result in tumors with an ILC-like morphology [132].
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oreover, deletion of p120 catenin in addition to E-cadherin and p53 did not accelerate
tumor formation, and the morphology of these triple-knockout tumors was predominantly
sarcomatoid [133]. This indicated that cytoplasmic p120 catenin is required for the de-
velopment of ILC in mice. A more promising candidate appears to be α-catenin, an
important link between the adherens junction and the actin cytoskeleton. Loss of α-catenin
in p53-deficient mammary tumor cells resulted in anchorage independence, constitutive
actomyosin contraction, and an ILC-like morphology [134].
Human ILCs are commonly associated with PI3K pathway mutations [3,22,24], mak-
ing these attractive targets to model ILC in mice. Multiple mouse models of ILC have been
generated by combining mammary-specific loss of E-cadherin with either expression of
hotspot mutations of Pik3ca (E545K or H1047R), Akt (E17K), or somatic deletion of the tu-
mor suppressor Pten [125–127]. In all models, the combination of E-cadherin loss and PI3K
pathway activation decreased mammary tumor latency and promoted the development
of tumors with classic ILC features. Tumors induced by E-cadherin loss and expression
of Akt (E17K) have a more solid ILC morphology and typically higher proliferation rates
than tumors induced by expression of mutant Pik3ca [126] or loss of Pten. In addition,
tumors induced by E-cadherin loss and expression of mutant Pik3ca or loss of Pten are
ER+ and have a gene expression profile similar to the luminal A subtype. In addition, the
mutant Pik3ca model has an immune-related molecular subtype combined with activation
of immune checkpoint pathways, making it an interesting model to study the therapeutic
potential of immune checkpoint inhibitors in ILC [126]. These tumors have not been tested
for responsiveness to hormonal therapies, so it remains to be determined whether they can
be used to study endocrine therapy resistance mechanisms. Interestingly, mutant PIK3CA
has been proven as a model for studying the immune-related molecular ILC subtype [126].
To identify novel ILC driver genes, an in vivo insertional mutagenesis screen yielded
multiple candidates, several of which were subsequently used to generate novel GEMMs
of ILC [128]. Two of these models, which combined mammary-specific loss of E-cadherin
with overexpression of truncated variants of Mypt1 or Aspp2, showed that a reduction in
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actomyosin contractility is sufficient to drive the malignant transformation of E-cadherin
deficient mammary epithelial cells [128,129]. The tumors typically displayed classic ILC
features but were not tested for ER expression or dependency. Interestingly, both models
showed rapid tumor initiation but slow tumor growth, a common characteristic of ILCs.
Additional loss of PTEN resulted in faster tumor initiation and larger tumors [129]. In vivo
validation of a third hit from the insertional mutagenesis screen, TRPS1, showed that while
TRPS1 expression is essential for the survival of mammary epithelial cells, combined loss
of TRPS1 and E-cadherin expression resulted in accelerated tumor development [130].
5.1.1. Orthotopic Transplantation of Mouse ILC Tumor Fragments into Syngeneic Mice
One of the main limitations of traditional GEMMs is developing mammary tumors
in multiple glands. These tumors arise and progress at different rates complicating both
the ability to test for drug efficacy and studying cancer metastasis. Transplantation of
tumor fragments from mouse ILCs into syngeneic wild-type mice has therefore been
utilized to study mechanisms of acquired drug resistance [90,135,136] and metastasis [137]
(Figure 3). One particular strength of this method is that these processes can be carried out
in an immunocompetent context enabling interrogation of novel immunotherapies and the
critical role of the immune system in cancer metastasis [29,138–140]. The transplantation of
tumor fragments works robustly for the p53-deficient mouse ILC models but is challenging
with models that have a classical ILC morphology. It is currently unclear why the classic
ILC models do not grow out consistently.
5.1.2. GEMM-Derived ILC Lines
In addition to in vivo studies, ILCs from the GEMMs mentioned above have also
been used to derive 2D and 3D cell lines [25,125,126,131]. The ILC cell lines derived from
K14-Cre;Cdh1F/F;Trp53F/F (KEP) tumors have been used extensively in follow-up studies
as they can be readily genetically modified and transplanted into mice, making them ideal
for mechanistic studies [108,132,141,142]. The classic ILCs from WAP-Cre;Cdh1F/F;PtenF/F
and WAP-Cre;Cdh1F/F;R26-LSL-Pik3caH1047R mice have been successfully used to culture
organoids/spheroids [125,126], but they do not give rise to classic ILCs when transplanted
back into mice, suggesting their limited use for in vivo studies (Table 4 and Supplementary
File S1).
5.1.3. Somatic ILC Models
GEMMs have played a critical role in advancing our understanding of tumorigenesis,
but they have several limitations. Traditional GEMMs are notoriously time-consuming
and expensive to establish. While the development of new strategies such as in vitro
modification of embryonic stem cells derived from existing GEMMs has accelerated the
process, it remains costly and laborious [143]. It has long been known that the mammary
gland structure allows for the administration of exogenous substances via intraductal
injections [144]. However, it was not until recently that this administration route was used
to generate somatic mouse models of ILC [127]. Intraductal injection of viruses encoding
for Cre-recombinase enables control of the number of mammary glands that will develop
tumors, thus overcoming a limitation of traditional GEMMs.
Furthermore, the injection of lentiviruses encoding candidate oncogenes allows for
rapid validation of driver genes or mutated variants without having to engineer new
GEMMs [145]. Finally, the development of CRISPR technology has exponentially increased
the possibilities for somatic modification of genes and their expression. Intraductal injection
of lentiviruses encoding guide RNAs targeting Pten or Myh9 in mice with mammary-
specific loss of E-cadherin and expression of Cas9 resulted in the formation of tumors with
a classic ILC morphology [127,128]. The limitation of this technique is that the efficiency is
lower than the traditional GEMMs, as not all injected glands develop tumors. More recent
advances in genome engineering, such as CRISPR-Cas9-based editors [146,147], have not
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yet been used to generate ILC mouse models, but it has been shown that they can be used
to generate PIK3CA hotspot mutations frequently seen in ILC patients [146].
6. Modeling ILC with Xenografts
Xenograft models in which cancer cells typically grow in immunodeficient mice
have revealed important aspects of ILC progression and therapy resistance mechanisms.
Four conventional routes of inoculation have been widely used to generate xenografts
by surgery: systemic (intracardiac injections through the left ventricle and intracarotid
through the internal carotid artery), local (renal capsule, intracranial, intra-bone marrow,
and intrailiac artery injection), under the skin (intradermic or subcutaneous), orthotopic
(mammary fat pad) and inside the milk ducts (Figure 3). Specifically for ovarian hormone-
dependent ER+ BCs, often, recipient mice require exogenous E2 supplementation for
successful tumor engraftment and growth [31]. These approaches mainly mimic E2 levels
found in premenopausal women in the luteal phase and frequently have deleterious effects
on the host. Researchers often use medium rich in selected growth factors, basement
membrane extract (BME), and Matrigel to increase engraftment efficiency. However, not
well-defined growth factors found in murine-derived BME and batch-to-batch variability
might support the preferential engraftment of specific ILC cell types and might lead to a
lack of reproducibility.
6.1. Cell Line-Derived Xenografts
Due to low tumor take rates, only a few ILC xenografts have been established and
are currently of limited utility for ILC research [31,148]. Among the few established
xenografts, following the conventional subcutaneous or fat pad implantation approaches,
are the IPH-926 cells [54]. IPH-926 cells injected subcutaneously recapitulated the linear
cord invasion pattern and the occasional intracytoplasmic lumina with central mucoid
inclusions, characteristic of human ILCs [34,54]. Upon E2 supplementation, the BCK4
cells injected into the mammary fat pad of NOD-SCID mice form ILC with mucinous
features [38,149], whereas CAMA1 cells grow poorly as xenografts [150]. MDA-MB-453
cells, injected subcutaneously, can only grow if suspended into Matrigel [151] while grow-
ing without hormone supplementation when injected into the mammary fat pads of cycling
female nu/nu mice [152].
Recently, it was demonstrated that the microenvironment is a key determinant for
the growth of ER+ BC by injecting normal breast cells or BC cells directly into the primary
milk ducts, which resemble the specific anatomic site where BCs arise from [153–157]. It
has been shown that intraductal injection enables the physiological growth of ER+ BC
cells and facilitates the study of the natural BC progression from primary tumor formation
to dormancy and metastases in clinically relevant organs [106,148,156,158,159]. Hitherto
a panel of BC cell lines representative of different subtypes have been injected directly
into the milk ducts of NSG female mice and led to their robust in vivo growth without
E2 repletion, including two widely used ILC cell lines (SUM-44PE and MDA-MB-134-VI)
and one ILC-like (MDA-MB-453) [154,160]. Histological analysis revealed that intraductal
xenografts progress from in situ to the invasive phase over several weeks and faithfully
resemble human lobular characteristic morphological patterns of a single file, pagetoid, and
targetoid spread [160,161]. Morphologically, ILC cell lines colonize the ductal tips and give
rise to grape-like structures, whereas E-cadherin-proficient NST cells cause widespread
dilation of host murine ducts. Notably, ILC xenografts stained highly positive for ER and
showed E2-inducible PR expression confirming the estrogen responsiveness of this model.
SUM-44PE and MDA-MB-134-VI metastasized to clinically relevant organs, including the
leptomeninges, GI tract, and ovaries. Over 10–12 months after initial intraductal injection,
tumor burden in distant organs was increased to levels comparable to those seen in the
primary tumor. Using the intraductal approach, global gene expression profiling of pure
primary ILC and NST xenografted cancer cells revealed ECM remodeling as a key tumor
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cell-intrinsic ILC feature. ILCs secrete proteins and enzymes that control their own matrix,
which opens new therapeutic strategies [160].
6.2. Patient-Derived Xenografts (PDXs)
Patient-derived xenograft (PDX) models overcome the limitations of cell line-derived
xenografts with essential applications to preclinical studies and inform patient care [162–164].
Typically, freshly dissected primary or metastatic BC tissue is implanted directly into an
animal, typically an immunocompromised mouse. Notably, the generated PDXs retain
the genetics, the polyclonality, and the intratumor heterogeneity of the originating human
tumors [165–168]. PDXs hold promise as a discovery and validation platform across
multiple institutions [148,169,170]. Biologically, the most critical challenge in developing
ILC PDXs is the substantially lower engraftment rate of ER+ compared to TN or HER2+
BCs. Moreover, ILCs develop over several years, so not surprisingly, ILC xenografted
tumors are notoriously slow-growing. To date, only a few ILC PDXs have been described
(Table 5).
For testing new agents and drug responses, BC fragments from a cohort of 200 samples
with a range of stages and histologies, including three TN-ILCs implanted directly into
the interscapular fat pad of adult female Swiss nude mice [171–173]. The generated PDXs
recapitulated the features of the original tumors, and the HBCx-7 model (p53 wild-type)
responded well to docetaxel treatment, pointing to a valuable preclinical drug testing
tool. ILC PDXs have also been generated subcutaneously in severe immunocompromised
NSG female mice in the presence of 8 mg/mL of E2 in the drinking water [174]. Several
PDXs, including seven ILCs, were also generated by initially embedded tumor samples in
Matrigel and then implanted subcutaneously into female NSG mice (Table 5) [175].
Table 5. ILC Cell Line-Derived and Patient-Derived Xenografts. Abbreviations: MA, malignant ascites; OvM, ovarian
metastases (*murine); BrM, brain metastases; ER, estrogen receptor; PR; progesterone receptor; ChR, chest recurrence;
NST, non-special type; SkR, Skin recurrence (chest wall); PrBC, primary breast cancer; PE, pleural effusion; LCIS; lob-
ular carcinoma in situ; n/a, not available; un: unspecified; SkC, skin right clavicle; AF, Ascitic fluid; EPFL, The École
polytechnique fédérale de Lausanne; ISREC, Swiss Institute for Experimental Cancer Research; IC, Institute Curie; MHH,
Institute of Pathology, Hannover Medical School; MBRC, The NIHR Manchester Biomedical Research Centre; WUSTL,
Washington University in St. Louis; HCI, Huntsman Cancer Institute; BCM, Baylor College of Medicine; ns, not specified;
Ref, reference(s). See also Supplementary File S1.
Name Tumor Tissue Biomarker (Model) Laboratory/Institute Implantation Site Ref.
Xenografts (cell lines)
SUM-44 PE ILC PE ER+/PR+/−/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [160]
MDA-MB-134-VI ILC PE ER+/PR+/−/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [160]
IPH-926 ILC MA ER−/PR−/HER2− Prof. M. Christgen/MHH Subcutaneous [34]
PDXs
T69 ILC PrBC ER+/PR+/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [176]
T73 ILC PrBC ER+/PR−/HER2+ Prof. C. Brisken/EPFL-ISREC Milk ducts [176]
T78 ILC PrBC ER+/PR+/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [176]
T85 ILC PrBC ER+/PR−/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [176]
T86 ILC PrBC ER+/PR+/HER2− Prof. C. Brisken/EPFL-ISREC Milk ducts [176]
LA-PDX1 ILC PrBC ER+/PR+/HER2− Prof. R. Iggo/BCI Milk ducts [177]
LA-PDX2 ILC PrBC ER+/PR+/HER2− Prof. R. Iggo/BCI Milk ducts [177]
LA-PDX3 ILC PrBC ER+/PR+/HER2− Prof. R. Iggo/BCI Milk ducts [177]
LA-PDX4 ILC PrBC ER+/PR+/HER2− Prof. R. Iggo/BCI Milk ducts [177]
BCM-3561 ILC un ER−/PR−/HER2ENRICHED Prof. M.T. Lewis/BCM Fat pad (mammary) [178]
BCM-4189 LCIS MA ER−/PR−/HER2ENRICHED Prof. M.T. Lewis/BCM Fat pad (mammary) [178]
HCI-005 MixedNST/ILC PE ER
+/PR+/HER2+ Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-006 MixedNST/ILC PE ER
+/PR+/HER2 (n/a) Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-011 NST PE ER+/PR+/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-013 ILC PE ER+/PR+/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-013-EI ILC PE ER−/PR−/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [168,179]
HCI-014 ILC PE ER−/PR−/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-018 n/a BrM ER−/PR−/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [179]
HCI-031 ILC/LCIS PE ER−/PR−/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [168]
HCI-031OV ILC OvM * ER−/PR−/HER2− Prof. A.L. Welm/HCI Fat pad (mammary) [168]
WHIM2/5 MixedNST/ILC BrM ER
−/PR−/HER2− Prof. M. Ellis/WUSTL Fat pad (mammary) [180]
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Name Tumor Tissue Biomarker (Model) Laboratory/Institute Implantation Site Ref.
WHIM9 MixedNST/ILC ns ER
+/PR+/HER2− Prof. M. Ellis/WUSTL Fat pad (mammary) [180]
WHIM13 NST (ILCfeatures) SkR ER
−/PR−/HER2− Prof. M. Ellis/WUSTL Fat pad (mammary) [180]
WHIM20 MixedNST/ILC SkC ER
−/PR−/HER2+ Prof. M. Ellis/WUSTL Fat pad (mammary) [180]
WHIM23 MixedNST/ILC SkC ER
−/PR+/HER2− Prof. M. Ellis/WUSTL Fat pad (mammary) [180]
HBCx-7 ILC PrBC ER−/PR−/HER2− Prof. E. Marangoni,Prof. MF. Poupon/IC
Fat pad
(Interscapular) [172]
HBCx-19 ILC PrBC ER+/PR−/HER2+ Prof. E. Marangoni,Prof. MF. Poupon/IC
Fat pad
(Interscapular) [172]
HBCx-36 ILC PrBC ER−/PR−/HER2+ Prof. E. Marangoni,Prof. MF. Poupon/IC
Fat pad
(Interscapular) [172]
Met BC 5 ILC AF ER+/PR+/HER2− Prof. R. Clarke/MBRC Subcutaneous [174]
Met BC 9 ILC AF ER+/PR+/HER2− Prof. R. Clarke/MBRC Subcutaneous [174]
Met BC 11 ILC AF ER+/PR+/HER2− Prof. R. Clarke/MBRC Subcutaneous [174]
Met BC 11 ILC AF ER+/PR+/HER2− Prof. R. Clarke/MBRC Subcutaneous [174]
The mammary fat pad stroma is a widely used injection site, which is considered a
more relevant site for BC engraftment than the skin (Table 6). However, the endogenous
mammary epithelium may inhibit the growth of implanted tumor cells [148], and an
epithelium-free cleared” fat pad is preferred [181].
Hence, thirty-two stably transplantable xenograft lines have been established by direct
injection into the “cleared” mammary gland in the absence of Matrigel, including one
LCIS and one ILC [178]. Given the emerging involvement of the HER2 pathway in part
of ILCs, global gene expression analyses identified both ILC PDXs as HER2-enriched, yet
their corresponding xenografts were HER2− (Table 5, Supplementary File S1). A recent
study used 54 BC chunks, including 5 ILCs, to generate PDXs by directly implanting the
tumors into the cleared fat pad [163,182]. Interestingly, most ILC PDXs developed in this
series harbor ESR1 alterations commonly implicated as therapy resistance drivers [183].
HCI-018, a brain-derived PDX with a low frequency (<10%) ESR1Y537S mutation can only
be established in vivo upon E2 supplementation. In HCI-005, E2 induces its growth, and
as in the patient, it also metastasizes to the lungs [179]. The HCI-013 was established from
a pleural effusion from a 53-year-old woman with metastatic ER+/PR+/HER2− ILC, stains
negative for E-cadherin, cytoplasmic p120 [59], and also depends on exogenous E2 for its
in vivo growth. HCI-013EI initially engrafted in ovariectomized mice is an exception as it
grew independent of E2. Finally, the TN HCI-031 ILC PDX shows widespread metastasis
including uterine horns, stomach, liver, brain, kidney, LN, and spontaneous metastasis to
the mouse ovary, a common site of ILC metastases, which generated the secondary HCI-
031OV PDX that took nine months to reach a tumor diameter of 2 cm. A series of BC PDXs
has been developed by injecting tumor cells into the humanized stroma and endogenous
epithelium-free (cleared) mammary fat pads [180,184], including four ILCs. Two of them
show high PR levels and carry an activating ESR1 mutation (WHIM20 ESR1Y537S and
WHIM24 ESR1E380Q). On the other hand, WHIM9 with a wild-type ESR1 locus but E2-
independent growth and resistance to fulvestrant showed negligible PR levels [180].
A significant challenge in developing ER+ PDXs is the substantially low engraftment
rate when tumor cells are xenografted subcutaneously or into the mammary fat pad. No-
tably, very few PDXs are derived from treatment-naïve ER+ luminal A ILCs. Direct injection
into the murine milk ducts established 21 ER+ intraductal PDXs, including 5 ILCs and one
mixed subtype. The histological analysis defined four main histopathological patterns:
flat, lobular, in situ, and invasive [176]. Markedly, the lobular pattern was characterized
by the pagetoid spread of lobular carcinoma in situ (LCIS), associated with intracellular
clear mucin-like vacuoles bestowing a signet-ring like appearance of the engrafted tumor
cells [176,185]. In another study, four ER+ ILC PDXs (Table 5, Supplementary File S1 were
generated using the MIND methodology with a 100% engraftment take rate, confirming
that ILC tumors engrafted well in the murine milk ducts and gave tumor foci in both
secondary and tertiary grafts [177]. Notably, when the same tumor cells were injected in
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parallel in the milk ducts and subcutaneously into the flanks of NSG mice, the only tumor
foci successfully formed was derived from the intraductal ILC models [177]. Therefore,
HR+ breast tumors, including luminal A, which is the majority of ILCs, can well engraft
and propagate in the microenvironment of the mammary milk ducts.
7. Other Animals
Sporadic BCs are well studied in dogs and cats, which, like domestic animals, often
undergo surgical tumor resections [2,186]. Overall, <10 cases of ILC or LCIS have been
described in free-range or domestic animals so far [2]. Over six years, Ressel and colleagues
reviewed nearly 4000 canine BCs and identified only three ILC cases [187]. Moreover,
three LCIS were identified in macaques in 16 neoplastic mammary gland lesions exam-
ined [188]. Recently, immune-deficient zebrafish have been used as a preclinical model to
evaluate patient-specific therapy responses [189]. In a recent article, the authors evaluated
the engraftment of six PDXs into prkdc−/−, il2rga−/− immune-compromised zebrafish,
including one therapy-resistant ER+/PR+/Her2−, ILC derived from circulating tumor cells
(CTCs) (BRx-07), which harbors activating mutations in PIK3CA and FGFR2 [190,191].
8. ILC Challenges
8.1. Molecular Mechanisms of ILC Drug Resistance
Endocrine-resistant variants of SUM-44PE and MDA-MB-134-VI have been generated
with long-term endocrine treatments in vitro. One of the first in vitro studies generated
tamoxifen resistance SUM-44PE cells by increasing concentrations of 4HT [192]. In this
model, comparative gene expression analysis with wild-type cells revealed reduced ex-
pression of ERα and increased ERRγ (estrogen-related receptor γ) expression, which was,
therefore, proposed that may mediate tamoxifen resistance. Moreover, endocrine-resistant
variants of MDA-MB-134-VI and SUM-44PE were also generated by long-term maintaining
the cells in hormone-deprived conditions. The resulting variants had an increased prolifer-
ative response to E2, and in this model, WNT4 expression was driven by activated nuclear
factor kappa-B signaling [193]. Additional analysis of the same models subsequently
identified activation and induction of several enzymes critical in fatty acid and cholesterol
metabolism for energy production. It, therefore, implicated lipid-metabolic processes as
drivers of estrogen-independent growth of ILC endocrine-resistant cells [194]. Notably
the long-term estrogen-deprived (LTED) ILC cells had higher clonogenic ability compared
to their parental cells pointing to the distinct characteristics of resistant cells. In another
study, SUM-44PE were cultured without E2 until their growth rate was independent of
the exogenous E2 [195]. These models are also characterized by changes in cholesterol
biosynthesis enzymes and cholesterol metabolites, suggesting that this pathway could
be a therapeutical target in endocrine-resistant ILC [195]. An important ILC resource for
studying endocrine resistance has been reported with the discovery of naturally occurring
ESR1Y537C and ESR1Y537S mutations in SUM-44 PE after the in vitro acquisition of resis-
tance to long-term-estrogen deprivation [51]. ESR1 mutations have been associated with
resistance to endocrine therapy, and in this study impacted on ESR1 binding to the genome
and altered the ESR1 interactome [50,51]. Of note, ESR1Y537S was inhibited by fulvestrant
but not by 4-OHT, pointing to de novo resistance. Moreover, preclinical in vitro models
using the MDA-MB-134-VI cells showed de novo tamoxifen resistance of this particular
cell line which overexpress FGFR1 due to high-level amplification of its locus [59]. Clini-
cally, FGFR1 amplifications have been reported as regulators of cell growth and mediators
of endocrine therapy resistance [58], and other members of the FGFR family members
of tyrosine kinase receptors such as FGFR4 are also overexpressed in ILC resistant cell
lines [196].
8.2. ILC Tumor Microenvironment
While cell lines, organoids, and animal models provide unique advantages for study-
ing ILC, they are still not ideal for all the basic and preclinical ILC research due to their
Cancers 2021, 13, 5396 18 of 35
particular limitations and modeling the tumor microenvironment (TME) presents a unique
challenge. For example, 2D and 3D cell line-based models and organoids typically lack
the complex ILC tumor–stroma interactions. The ideal ILC model will need to be inclusive
of the various cellular components and ECM [197], and in vivo models better mimic this
scenario (Table 6). Nevertheless, ILC GEMMs are based on murine TME, and PDXs are
developing into immunocompromised hosts (Table 6). To overcome these limitations, we
will need, for example, to successfully reconstitute a patient-matched immune system in
ILC PDXs.
8.3. Modeling ILC Dormancy and Metastasis
As noted earlier, ILC is characterized by distinct clinical features of late recurrence [198].
The comprehensive understanding of the biology of the dormant ILC cells and the molec-
ular mechanisms of metastatic ILC relapse, as described below, is yet largely unclear.
Therefore, research on metastatic aspects of lobular carcinomas is of utmost importance
because they account for most ILC-related deaths.
In vivo models are of particular interest since they can provide insights into the com-
plex mechanisms of events of cancer progression, including dormancy and metastasis.
However, the generation of mouse models that recapitulate the unique features of ILC
metastases has been challenging. GEMMs provide a valuable resource for modeling metas-
tasis as they allow both tumor cell-autonomous and stromal influences to be modeled
at all stages of the metastatic cascade [199,200]. The early GEMMs of ILC show spread
to the gastrointestinal tract and peritoneum in common with what is seen in the human
disease and common sites such as lung and bone marrow [25,131]. This is also evident in
GEMMs incorporating PI3K pathway mutations [125]. Dormancy has not been explicitly
studied using ILC GEMMs as the growth of the primary tumor(s) is typically prohibitive.
A significant advance in the field has been the development of orthotopic transplanta-
tion of GEMM-derived tumor fragments into syngeneic mice [201], which, when coupled
with resection of the primary tumor, provides a much more tractable model for study-
ing dormancy and metastasis and their response to therapy [136,137]. This allows the
development of slow-growing metastases without sacrificing the animals due to the rapid
growth of the primary tumor. The use of immunocompetent hosts has led to identify-
ing essential roles for the immune system in controlling metastatic outgrowth using the
K14cre;Cdh1F/F;Trp53F/F model [138,139]. This approach has been extended to cell lines
derived from the KEP model [202,203]. Interestingly, following orthotopic transplantation,
the spread was predominantly to the bone, while the KEP cells could also colonize the
bone following intracardiac and intratibial transplantation [202].
Metastasis has also been reported in few cases of BC PDX models generated by subcu-
taneous or fat pad implantation. However, there is a predilection for spread to the lungs
and lymph nodes, and typically, they do not fully recapitulate the pattern of metastasis seen
in the patient [178,204,205]. In most cases, the metastatic spread is monitored histologically
and in a limited number of organs, and more widespread micrometastatic disease may
be present. Indeed, in an ILC PDX model (HCI-013) use of Alu-qPCR to detect human
sequences suggested widespread dissemination to many different organs, including to the
thorax, ovaries, peritoneum, GI tract, and bone, which were not detected histologically or
via luciferase imaging (Gomez-Cuadrado, unpublished data). Recently, an ILC PDX model
(HCI-031) was established from the pleural fluid of a patient who developed metastases
in the fallopian tubes, bones, pleura, liver, and brain. A metastatic variant (HCI-031OV)
was then derived from a spontaneous metastasis to the mouse ovary developed from the
HCI-031 PDX. This metastatic subline retained the same genomic driver mutations, had
similar gene expression profiles as the parental PDX model, and was able to spontaneously
metastasize back to the ovary following injection into the cleared fat pad [206].
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Typically, xenograft models using human cancer cell lines rarely metastasize in tissues
other than the lungs. However, recent studies have shown that intraductal implantation
of the MDA-MB-134-VI and SUM-44 PE cell lines leads to their metastatic spread to the
leptomeninges, adrenal glands, gastrointestinal tract, ovaries, and the peritoneal cavity—
sites of metastasis commonly seen in human disease [160,161,207]. This exciting advance
provides a way forward for research into the underlying biology of metastatic disease
progression and as a more tractable platform for testing new potential therapies. For
example, the use of luciferase imaging of multiple organs demonstrated that lysyl oxidase
inhibition reduced the metastatic burden of ILC tumor-bearing animals [160]. These models
represent a significant advance in studying the biology of the dormant ILC cells since there
is a latency period of up to 5 months before overt metastases are detected. Again, with
the caveat that the use of severely immunocompromised mice hampers the study of the
immune system’s role in ILC dormancy. Of note, a similar approach was taken with ILC-
derived PDX models where spontaneous micro-metastatic spread was found resembling
the tumor of origin in various organs, including lungs, bones, brain, and liver following
intraductal implantation [31,176].
The study of CTCs and disseminating tumor cells (DTCs) in PDX models provide an
additional route to studying metastatic dissemination in a preclinical setting [208]. Of note,
ex vivo culture of CTCs from patients with ILC has been reported. When implanted into
mice using conventional routes, these CTC-derived xenografts failed to metastasize [191]
but grew and metastasized when implanted intraductally [80]. To our knowledge, DTCs
studies have not yet been reported for ILC PDX models and, therefore, would be important
to model it in future studies.
9. Strengths and Limitations of Different ILC Models
Existing ILC models, including cell lines, organoids, and in vivo models, have created
unprecedented opportunities for studying the molecular mechanisms of disease progres-
sion (Table 6). However, there is concern that only a minority of currently available human
BC cell lines used as ILC models are actually of ILC origin. The few ILC models that exist
grow very slowly, making them unattractive models. In addition, since they derive from
late metastatic disease, they model end-stage ILC having a spectrum of mutations not found
in primary ILC (Table 2 and Supplementary File S1). Moreover, ILC lines cannot model
the full tumor complexity, and few ILC organoids that exist are not yet comprehensively
studied for their endocrine responses (Table 6).
Similarly, while there are adequate in vivo models for other BC subtypes, e.g., TNBC,
the field traditionally lacks ER+ models, particularly for luminal A subtype that is the
majority of ILCs. Direct implantation into the murine milk ducts rather than subcutaneous
or fat pad injections recapitulate the complete metastatic capability of ILCs and better
reflect the tumor heterogeneity. However, these models lack a functional immune system,
limiting their efficacy for testing immunotherapies. Table 6 provides a comprehensive
summary of the key advantages and limitations of widely used ILC models presented in
this review.
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Table 6. Experimental ILC models. Abbreviations: SM, spontaneous metastasis; EM, experimental metastasis; GEMMs, genetically engineered mouse models; PDXs, Patient-derived
xenografts; E2, estradiol. Color code: green, cell lines; orange, organoids; grey, GEMMs; purple, xenografts, and PDXs; white, implantation sites.
ILC Models Major Experimental Pros Major Experimental Cons Ref.
Cell lines (in vitro)
• Easy to work with
• Well characterized
• High-throughput drug screens
• A high degree of variation across cell line strains
• Lack of tumor heterogeneity
• Lack of the complex ILC–stroma interactions
• Not fully represent human cancers complexity
[33,34,36,37,39,63]
Organoids • Captures complex 3D cellular interactions
• Lack of the complex ILC–stroma interactions
• Variations in culture conditions
• Overgrowth by healthy epithelial organoids




• Captures complex ILC tumor–stroma interactions
• Easily manipulated (mouse germline) to induce
overexpression or knockout of target genes and study
them in the context of an intact mammalian organism




• Fast growth of the tumor cells at the primary site
• Development of mammary tumors in multiple glands





• Easy to work with
• Well-characterized cell lines
• Studies on metastasis
• Studies on endocrine resistance in vivo
• Time-consuming




• Maintain clonal diversity of the original tumors
• Serial transplantation
• Preclinical testing of ILC therapies
• Studies on metastasis
• Studies on endocrine resistance in vivo
• Large amount of resources
• Time-consuming
• Immune deficient
• Limited ILC tissue quantity
[34,153,154,160,163,172,174–176,178,179]
Implantation Sites
Subcutaneous (SM) • Easy to perform
• Low take rate
• Ectopic implantation
• Circumvent the early steps of the metastatic cascade
• No recognizable architectural ILC features





Cancers 2021, 13, 5396 21 of 35
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ILC Models Major Experimental Pros Major Experimental Cons Ref.
Mammary fat pad (SM)
• Orthotopic
• The anatomical site reflects human breast
• Low take rate
• Circumvent early steps of tumor progression (e.g., LCIS)
• Immune deficient
• Low take rate
• Need for exogenous E2 supplementation (pre-menopause
levels)
[178,179]
Injection into the milk ducts
(SM)
• Transplantation in the proper anatomical context
where tumor arises
• High take rate
• Exogenous E2 supplementation is not a prerequisite
for ILC in vivo establishment
• ILC histologies
• Recapitulates the complete tumor progression and
metastatic cascade
• Spontaneous metastasis in clinically relevant
sites/organs
• Intraductal injection skills
• Immune deficient [154,160,176]
Tail vein (EM)
• Easy to perform
• Fast systemic distribution of cells to various organs
• Absence of primary tumor
• Circumvent early steps of the metastatic cascade
• A high number of cells injected directly into the circulation and
rapidly colonize an organ/tissue
• Mainly lung metastasis
[207]
Intracardiac (EM)
• Fast systemic distribution of cells to various organs
• Absence of primary tumor
• Circumvent early steps of the metastatic cascade
• A high number of cells injected directly into the circulation and
rapidly colonize an organ/tissue
• Mainly brain and bone metastasis
• Invasive technique
[207]
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10. ILC Initiatives and Repositories of ILC Models
To understand the full potential of ILC models, we should ensure their broad availabil-
ity and dissemination to the research community. However, the lack of rigorous standards
for reporting on PDX models hampered researchers’ finding relevant PDX models and as-
sociated data, including ILC PDXs [170]. The European Lobular Breast Cancer Consortium
(ELBCC) aims to bridge this gap in translational ILC research and provide an unprece-
dented clinical impact due to the streamlining of the “from bench-to-bedside” principle to
enable uniform diagnosis and tailored treatment for patients with ILC [209]. To this aim
LOBSTERPOT, a COST-funded (European Cooperation in Science and Technology) action
initiated by the ELBBC, proposes to combine discovery science, translational studies, and
clinical implementation to improve the understanding, diagnosis, treatment, and prognosis
of women suffering from ILC; https://www.cost.eu/actions/CA19138.
When generating ILC models, emphasis should be placed on quality assurance, careful
documentation with associated metadata, and genetic characterization. This documen-
tation will facilitate the data-informed design of the appropriate ILC model to examine
preclinical drug responses of primary tumors and metastases. Although several reposito-
ries have been developed recently (Appendix A), a centralized specific ILC public model
repository is required for the reporting, quality control, and standardized use of cell lines,
organoids, and ILC animal models [170]. To this end, it will be crucial to share knowledge
on the appropriate use of ILC models for immune assessments, dormancy, or treatment
of established tumors and metastases. Finally, limitations to each model (e.g., limited
metastatic potential, the time needed from initial engraftment to micro/macro metastasis)
should also be thoroughly addressed.
11. Discussion
ILC models have proved useful for preclinical studies and have provided findings
that can positively affect clinical management. However, as noted earlier in this review,
although valuable, the few available ILC models all have limitations. For example, cell
lines remain a powerful tool for BC research however, there is an increased risk of in vitro
genomic evolution [30]. The number of available ILC models remains limited, and the
widely used models do not represent primary nonmetastatic ILCs with genetic repertoire
such as wild-type p53, activating PIK3CA/HER2 mutation, and low-grade treatment-naïve
ER+ luminal A ILCs. Given the challenges in developing new ILC cell lines, we characterize
current models in the ILC Cell Line Encyclopedia (ICLE). The ongoing ICLE project is
mirrored on the successful Cancer Cell Line Encyclopedia (CCLE) [now named DepMap—
https://depmap.org/portal/], which unfortunately included only two ILC cell line models.
Using similar approaches, we plan to integrate the ICLE cell line results with CCLE. We are
performing comprehensively molecular profiling of a total of 17 ILC and ILC-like cell lines,
yet preliminary data show that they have genetic features of ILC such as mutation of CDH1.
The final product will be a publicly available website with comprehensive information
about DNA, RNA, and protein expression in a large panel of BC cell lines. We will also
combine this with limited phenotypic data to ensure that researchers can readily find the
most appropriate cell line model for their research.
Significant advances have been made in the ex vivo BC modeling; however, due to the
loss of E-cadherin expression, ILC has defective adherens junctions, which impedes their
proper 3D formation, development, and expansion of non-coherent ILC organoids, and
only a few models have been successfully propagated. We expect an increased number of
well-characterized ILC PDOs in the near future.
Modelling ILC with GEMMs, where the mouse germline can be readily manipulated
to induce overexpression or knockout of target genes, is an essential tool for understanding
ILC biology [210]. However, tumors typically harbor numerous driver lesions, affect-
ing their sensitivity to treatments [211]. As such, it remains crucial to establish complex
mouse models incorporating multiple driver genes that are frequently encountered to-
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gether in ILCs. Moreover, current ILC-specific trials (NCT03620643 and NCT04551495) are
conceptually based on functional findings from the conditional ILC mouse models.
PDXs largely recapitulate the polygenic architecture of human tumors and closely
resemble patient tumor molecular and histological features [30,168]. The realization that
cell-cell and cell-matrix interactions within the complex tumor environment regulate
primary tumor growth, metastatic spread, and response to therapy provides potential
new ILC therapeutic opportunities [160,212–214]. Similarly, as we now understand more
about the unique ILC tumor microenvironment, it will be necessary to model the different
immune cell populations, cancer-associated fibroblasts, and matrix components [29,160,
213,215]. Moreover, the establishment of PDX models from unique ILC metastatic sites
such as leptomeninges and ovaries would provide additional information on how the
tumor-related metastatic niche controls the outgrowth of disseminated ILC cells. ILC
post-mortem tissue donation programs such as the recent interventional (Clinical Trial)
named UPTIDER (https://clinicaltrials.gov/ct2/show/NCT04531696) will further support
basic and translational research to model ILC dormancy and metastasis, to understand
drug resistance, and develop new effective therapies [216]. This is particularly important in
ILC progression often characterized by an increased risk of late recurrence, attributed to the
reawakening of dormant disseminated tumor cells after prolonged periods. We anticipate
that PDX models will help us better understand the mechanism of anti-endocrine therapies
studies and the exquisite ILC sensitivity to estrogens plus progesterone treatments [217].
In that direction, we envisage that the intraductal model will help us study early in situ
lesions that have a repertoire of somatic genetic alterations similar to that of ILCs [218].
Moreover, rare ILC cases should now be studied, including male ILC, which needs further
investigation [219–221]. To our knowledge, there is only one unpublished male PDO
(Table 3); yet, it has not been used to develop a PDX and needs further characterization.
Together, the potential use of humanized ILC mouse models may improve the predic-
tion of the therapeutic efficacy of novel agents. The further development and refinement of
the complex ILC animal models will provide understanding and identification of metastatic
pathways, new therapeutic targets, and conceivably personalized cancer therapy.
12. Conclusions
We lack preclinical ILC models to develop new effective treatments. We envisage that
lobular research initiatives, such as LOBSTERPOT-CA19138 action, will play an essential
role in understanding the existing in vitro and in vivo ILC models and developing new
models. Moreover, the growing knowledge about the challenges and the opportunities of
ILC models that we describe in this review, together with the development of early- and
metastatic-stage clinical trials specifically for patients with E-cadherin-deficient tumors,
presents an exciting opportunity for further improving and expanding ILC models.
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HER2 Human Epidermal Growth Factor Receptor 2
PDX Patient-Derived Xenograft
PDO Patient-Derived Organoid
GEMMs Genetically Engineered Mouse Models
Xenograft
Human-derived cells and tissues transplanted into a recipient of another species
(mice, rats, zebrafish, etc.)
CaMa Cancer Mammary
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
ELBCC The European Lobular Breast Cancer Consortium
COSMIC Catalogue Omf Somatic Mutations In Cancer
ECM Extracellular matrix
CTC Circulating Tumor Cell
DTC Disseminating Tumor Cell
HCMI Human Cancer Models Initiative
KCLB Korean Cell Line Bank
CCLE Cancer Cell Line Encyclopedia
RIKEN Rikagaku Kenkyūjo Cell Bank
ATCC American Type Culture Collection
Appendix A
Appendix A.1. Initiatives and Models Repositories
1. Platform to bring together discovery scientists, translational researchers, and clinical
experts, with the ultimate goal to improve the understanding, diagnosis, treatment,
and prognosis of women who have Invasive Lobular Breast Cancer—http://www.el
bcc.org/
2. Lobular Breast Cancer: Discovery Science, Translational Goals, Clinical Impact—
https://www.cost.eu/actions/CA19138/#tabs\T1\textbar{}Name:overview
3. The Lobular Breast Cancer Alliance (LBCA) has compiled a reference list of research
publications related to lobular breast cancer—https://lobularbreastcancer.org/
4. Patient-Derived Xenograft and Advanced In Vivo Models (PDX-AIM) Core of Baylor
College of Medicine. PDX Portal is designed to allow investigators to browse the
various organ site-specific PDX collections—https://pdxportal.research.bcm.edu/p
dxportal/?dswid=8822
5. PDX Finder—a comprehensive open global catalogue of PDX models and their associ-
ated data across resources—https://www.pdxfinder.org/
6. The PDXNet comprises six PDX Development and Trial Centers (PDTCs) and the
PDX Data Commons and Coordinating Center (PDCCC), and is working with the
National Cancer Institute to translate PDX studies to clinical trials.
7. EurOPDX Consortium is an initiative of translational and clinical researchers counting
18 not-for-profit cancer centers and universities as members across Europe and the
US, https://www.europdx.eu/
8. The Human and Mouse Linked Evaluation of Tumors (HAMLET) Core developed by
Prof. Matthew Ellis, M.D., Ph.D., and Shunqiang Li (Director: Shunqiang Li, Ph.D.—
https://digitalcommons.wustl.edu/hamlet/
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9. Public Repository of Xenografts (ProXe) is an open-source website designed to dis-
seminate information relevant to patient-derived xenografts (PDXs) and PDXs from
patients with leukemia or lymphoma by the Weinstock Laboratory. Many models
are being licensed to the Jackson Laboratories for industry-scale purposes, including
distribution on a fee-for-service basis.
10. Cell Model Passports—a hub for clinical, genetic, and functional datasets of preclinical
cancer models, https://cellmodelpassports.sanger.ac.uk/ [222].
11. NCI Patient-Derived Models Repository (PDMR)—https://pdmr.cancer.gov/
Appendix A.2. Companies
1. Novartis Institutes for Biomedical Research PDX Encyclopedia (NIBR PDXE), an
industry-led initiative that includes approximately 1000 models
2. Horizon (The WHIM, Washington University Human-in-Mouse, collection developed
by Shunqiang Li and Matthew Ellis at Washington University and published in Cell
Reports). ILC models are reported in Table 5 and Supplementary File S1.4.
3. XenOPAT (a spin-off of the Institute of Biomedical Research (IDIBELL), the Catalan
Institute of Oncology (ICO) and then University Hospital of Bellvitge).
4. Crown Bioscience Inc., http://hubase.crownbio.com/
5. Champions TumorGraft® Database—https://database.championsoncology.com/m
odels/filter. *Run PDX studies (in-house) to test experimental oncology compounds.
6. Charles River has more than 400 fully characterized proprietary patient-derived
xenografts (PDXs), representing major histotypes and tumors and providing extensive
background and characterization. No ILC model was found in the database.
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